DDInter1042 DDInter93
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
Anagrelide {u} (Compound) upregulates {v} (Gene) HMG20B
Anagrelide {u} (Compound) is included by {v} (Pharmacologic Class) Phosphodiesterase 3 Inhibitors
Anagrelide {u} (Compound) downregulates {v} (Gene) TM9SF2
Anagrelide {u} (Compound) causes {v} (Side Effect) Distress gastrointestinal
Anagrelide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milrinone
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Vorapaxar
Anagrelide (Compound) treats hematologic cancer (Disease)
Anagrelide (Compound) binds CYP1A2 (Gene)
Anagrelide (Compound) upregulates HMG20B (Gene)
Anagrelide (Compound) is included by Phosphodiesterase 3 Inhibitors (Pharmacologic Class)
Anagrelide (Compound) downregulates TM9SF2 (Gene)
Anagrelide (Compound) causes Distress gastrointestinal (Side Effect)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Milrinone
Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar